Currently, there is an ongoing trial to test enzalutamide plus alpelisib (an α-specific PI3K inhibitor) in AR-positive/PTEN-positive patients with metastatic TNBC or ERα-positive and/or PR-positive/HER2-negative breast cancer (NCT03207529). This evidence concerns the gene AR and breast cancer.